346 589

Cited 47 times in

Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells

Authors
 Sang Kyum Kim  ;  Honsoul Kim  ;  Da-hye Lee  ;  Tae-shin Kim  ;  Tackhoon Kim  ;  Chaeuk Chung  ;  Gou Young Koh  ;  Hoguen Kim  ;  Dae-Sik Lim 
Citation
 PLOS ONE, Vol.8(10) : e78130, 2013 
Journal Title
PLOS ONE
Issue Date
2013
MeSH
Aldehyde Dehydrogenase/antagonists & inhibitors ; Aldehyde Dehydrogenase/metabolism* ; Analysis of Variance ; Animals ; Blotting, Western ; Carcinoma, Pancreatic Ductal/drug therapy* ; Cell Line, Tumor ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Disulfiram/pharmacology* ; Drug Delivery Systems/methods ; Drug Resistance, Neoplasm/physiology* ; Flow Cytometry ; Humans ; Immunohistochemistry ; Mice ; Neoplastic Stem Cells/enzymology* ; Pancreatic Neoplasms/drug therapy* ; Real-Time Polymerase Chain Reaction
Keywords
Aldehyde Dehydrogenase/antagonists & inhibitors ; Aldehyde Dehydrogenase/metabolism* ; Analysis of Variance ; Animals ; Blotting, Western ; Carcinoma, Pancreatic Ductal/drug therapy* ; Cell Line, Tumor ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/pharmacology ; Disulfiram/pharmacology* ; Drug Delivery Systems/methods ; Drug Resistance, Neoplasm/physiology* ; Flow Cytometry ; Humans ; Immunohistochemistry ; Mice ; Neoplastic Stem Cells/enzymology* ; Pancreatic Neoplasms/drug therapy* ; Real-Time Polymerase Chain Reaction
Abstract
Human pancreatic ductal adenocarcinoma (PDAC) is a cancer with a dismal prognosis. The efficacy of PDAC anticancer therapies is often short-lived; however, there is little information on how this disease entity so frequently gains resistance to treatment. We adopted the concept of cancer stem cells (CSCs) to explain the mechanism of resistance and evaluated the efficacy of a candidate anticancer drug to target these therapy-resistant CSCs. We identified a subpopulation of cells in PDAC with CSC features that were enriched for aldehyde dehydrogenase (ALDH), a marker expressed in certain stem/progenitor cells. These cells were also highly resistant to, and were further enriched by, treatment with gemcitabine. Similarly, surgical specimens from PDAC patients showed that those who had undergone preoperative chemo-radiation therapy more frequently displayed cancers with ALDH strongly positive subpopulations compared with untreated patients. Importantly, these ALDH-high cancer cells were sensitive to disulfiram, an ALDH inhibitor, when tested in vitro. Furthermore, in vivo xenograft studies showed that the effect of disulfiram was additive to that of low-dose gemcitabine when applied in combination. In conclusion, human PDAC-derived cells that express high levels of ALDH show CSC features and have a key role in the development of resistance to anticancer therapies. Disulfiram can be used to suppress this therapy-resistant subpopulation.
Files in This Item:
T201304415.pdf Download
DOI
10.1371/journal.pone.0078130
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sang Kyum(김상겸) ORCID logo https://orcid.org/0000-0003-0768-9923
Kim, Hon Soul(김한솔)
Kim, Hogeun(김호근)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88645
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links